Dorphan S.A. was founded in 2011 by the members of the Swiss Sanfilippo Foundation in order to discover and pursue the development of drug candidates for orphan and rare genetic diseases. The company R&D activities are built on worldwide innovative research to identify, evaluate and develop preclinical molecules and deliver promising drug candidates to patients.
Industry: Gene Therapy
Headquarters: Vaud
Estimated Revenue: Less than $1M

Visit Website
Register and Claim Ownership